Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317057 | 0.84 | MAPT (0.35) | NPC1MAPTDGAT1 | |
| Ammonia Solution, Strong SCHEMBL2320645 | 0.81 | MAPT (0.31) | MAPTDGAT1 | |
| SCHEMBL2315378 | 0.79 | TDP1 (0.36) | NPC1MAPTDGAT1 | |
| SCHEMBL2316810 | 0.77 | LCK (0.35) | NPC1 | |
| SCHEMBL2319413 | 0.74 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL2317105 | 0.72 | CHEK1 (0.34) | NPC1DGAT1 | |
| SCHEMBL2315228 | 0.72 | KCNH2 (0.37) | NPC1DGAT1 | |
| SCHEMBL2317262 | 0.71 | BRD4 (0.36) | NPC1MAPTDGAT1 | |
| SCHEMBL2320195 | 0.71 | ALOX15 (0.37) | NPC1MAPTDGAT1 | |
| SCHEMBL16261059 | 0.70 | NPC1 (0.39) | NPC1MAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | NPC1 685/4885MAPT 3798/4885DGAT1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.